- Title: Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among 1
- 2 previously infected or vaccinated employees
- Authors: Kojima N¹; Roshani A²; Brobeck M²; Baca A²; and Klausner JD³ 4
- ¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095 6
- 7 ² Curative Inc., San Dimas, CA
- ³ Department of Population and Public Health Sciences, University of Southern 8
- 9 California, Keck School of Medicine, Los Angeles, 90033
- **Keywords:** COVID-19; SARS-CoV-2; Incidence; Reinfection; Prior Infection; 11
- 12 Vaccination

5

10

Abstract (Words 350)

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

Introduction: The protective effect of previous infection versus vaccination is poorly studied. Among a clinical laboratory that has been conducting routine workforce screening since the beginning of the pandemic, we aimed to assess the relative risk of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection among individuals who were SARS-CoV-2 naïve, previously infected, or vaccinated. Methods: Using an electronic laboratory information system, employees were divided into three groups: (1) SARS-CoV-2 naïve and unvaccinated, (2) previous SARS-CoV-2 infection, and (3) vaccinated. Person-days were measured from the date of the employee first test and truncated at the end of the observation period. SARS-CoV-2 infection was defined as two positive SARS-CoV-2 PCR tests in a 30-day period. Individuals with fewer than 14 days of follow up were excluded. Incidence estimates and the 95% confidence intervals were calculated using the Poisson Exact equation. The incidence rate ratio (IRR) was used as a measure of association between groups. Analyses were performed on StataSE (StataCorp, College Station, TX). Results: We identified 4313, 254 and 739 employee records for groups 1, 2, and 3, respectively. The median age of employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation period, 254, 0, and 4 infections were identified among groups 1, 2, and 3, respectively. Group 1 had an incidence of 25.9 per 100 personyears (95% CI: 22.8-29.3). Group 2 had an incidence of 0 per 100 person-years (95% CI: 0-5.0). Group 3 had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR of reinfection among those with previous infection compared to SARS-CoV-2 naïve was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to SARS-CoV-2

naïve was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to prior SARS-CoV-2 was 0 (95% CI: 0-4.98).

Conclusion: Previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with decreased risk for infection or re-infection with SARS-CoV-2 in a routinely screened workforce. The was no difference in the infection incidence between vaccinated individuals and individuals with previous infection. Further research is needed to determine whether our results are consistent with the emergence of new SARS-CoV-2 variants.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Main Text (930 words) Introduction Prior reports have found lower rates of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections among those with prior infection or vaccination. 1,2 Although an association between vaccination and reduction of SARS-CoV-2 incidence has been well described, how the incidence among individuals with previous infection compares to vaccinated individuals remains unclear. **Methods** In March 2020, Curative, a SARS-CoV-2 testing company, began routinely screening its workforce with an Food and Drug Administration-authorized SARS-CoV-2 polymerase chain reaction (PCR)-based test.³ The workforce was screened daily. A standardized employee testing database was implemented on 8 May 2020. On December 15, 2020, vaccination with either the BNT162b2 or mRNA-1273 vaccines became available. Routine screening has continued through July 2021. The SARS-CoV-2 naïve, unvaccinated group was defined as any employee without previous infection that tested from 8 May up to 15 December 2020 (when vaccination became available). The previously infected, unvaccinated group was defined as any employee with documented previous SARS-CoV-2 infection (at least 2 positive PCR tests) between 8 May to 15 December 2020. The vaccinated group was defined as any employee with documented completion of vaccination through 1 July 2021.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

Person-days were measured from the first test date to last test date up to December 15th, 2020 for groups 1 and 2 and up to July 1, 2021 for group 3. We defined SARS-CoV-2 infection as two positive PCR tests in a 30-day period. Individuals with fewer than 14 days of follow up were excluded. Incidence in 100 person-years with 95% confidence intervals (95% CIs) was calculated with the Poisson Exact equation. The incidence rate ratio (IRR), the ratio of confirmed COVID-19 cases per 100 person-years of follow up with 95% CIs, was used as a measure of association between groups. Analyses were performed on StataSE (StataCorp, College Station, TX). The study of de-identified electronic medical record data was determined by the Advarra institutional review board (Pro00054560) to be exempt from review. Results We identified 4313, 254 and 739 employee records for the naïve and unvaccinated group (Group 1), the previously infected and unvaccinated group (Group 2) and the vaccinated without previous infection group (Group 3), respectively. The median age of employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation period, 254, 0, and 4 SARS-CoV-2 incident infections were identified among Groups 1, 2, and 3, respectively. (Table). The naïve, unvaccinated group had a SARS-CoV-2 incidence of 25.9 per 100 personyears (95% CI: 22.8-29.3). The previously infected, unvaccinated group had an incidence of 0 per 100 person-years (95% CI: 0-5.0). The vaccinated group had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR of reinfection among

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

those with previous infection compared to those SARS-CoV-2 naïve was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to those SARS-CoV-2 naïve was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to those previously SARS-CoV-2 infected was 0 (95% CI: 0-4.98). **Discussion** In the workplace setting, we observed a lower incidence of SARS-CoV-2 infection among those with previous SARS-CoV-2 infection or SARS-CoV-2 vaccination with either the BNT162b2 or mRNA-1273 vaccines. Either prior infection or vaccination was associated with a dramatic decreased risk for infection or re-infection with SARS-CoV-2. The was no difference in the incidence of SARS-CoV-2 infection or re-infection between individuals who were vaccinated and individuals with prior SARS-CoV-2 infection. respectively. Our findings are similar to other studies that compared the incidence of SARS-CoV-2 infection among those with prior SARS-CoV-2 infection and vaccination to unvaccinated antibody seronegative individuals. In a study conducted in Oxfordshire, UK, researchers reported that they found no differences in immunity induced by natural infection and vaccination with the BNT162b2 or ChAdOx1 nCOV-19 vaccines among a cohort of 13,109 healthcare workers. Another group of researchers studying a group of 52,238 employees of the Cleveland Clinic Health System found that those with previous SARS-CoV-2 infection and those who were vaccinated had lower rates of SARS-CoV-2 infection compared to those who were SARS-CoV-2 naïve and unvaccinated.⁵

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

After vaccination or natural infection, many mechanisms of immunity exist including humoral and cellular immunity.⁶⁻⁸ It is known that SARS-CoV-2 infection induces specific and durable T cell immunity against multiple SARS-CoV-2 spike (S) protein targets (or epitopes) as well recognition of other SARS-CoV-2 proteins. The broad diversity of Tcell viral recognition serves to enhance protection to SARS-CoV-2 variants, with recognition of at least three SARS-CoV-2 variants (B.1.1.7 [U.K.], B.1.351 [South Africa], and B.1.1.248 [Brazil]).9 Additionally, a memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection that is consistent with immune persistence. 10 Our findings were limited by the observational nature of the study. It is possible, but unlikely, that employees could have tested positive outside of the employee testing program. In addition, because allocation to each exposure group was not random, there might be differences between groups in the risk of repeat exposure over time. The study was strengthened by the high incidence among those naïve and unvaccinated, the large sample size and large number of person-years of follow up in each group. Conclusion We found a strong association between prior SARS-CoV-2 infection and vaccination for SARS-CoV-2 with either BNT162b2 or mRNA-1273 and the reduced incidence of SARS-CoV-2 when compared to those naïve and unvaccinated to SARS-CoV-2. The was no difference in the incidence of SARS-CoV-2 between individuals who were vaccinated and individuals with prior SARS-CoV-2 infection. Combined with prior

studies, our findings should provide increased confidence that those previously infected are at very low risk for repeat infection. Further research is needed to determine whether our results are consistent with the emergence of new SARS-CoV-2 variants.

Declarations

Declaration of competing interests

NK is a consultant for Curative. AR, MB, and AB are employed by Curative. JDK is an independent consultant and serves as the Medical Director of Curative.

Funding

None

Acknowledgements

The staff at Curative Inc.

References

- 153 1. Qureshi Al, Baskett WI, Huang W, et al. Re-infection with SARS-CoV-2 in
- Patients Undergoing Serial Laboratory Testing. Clin Infect Dis. Apr 25
- 155 2021;doi:10.1093/cid/ciab345
- 156 2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a
- Nationwide Mass Vaccination Setting. *N Engl J Med.* Apr 15 2021;384(15):1412-1423.
- 158 doi:10.1056/NEJMoa2101765
- 159 3. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swab
- Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal
- Swab Specimens for the Detection of SARS-CoV-2. *Clin Infect Dis.* Oct 19
- 162 2020;doi:10.1093/cid/ciaa1589
- 163 4. Lumley SF, Rodger G, Constantinides B, et al. An observational cohort study on
- the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare
- workers by antibody and vaccination status. *Clin Infect Dis.* 2021;
- 166 doi:10.1093/cid/ciab608
- 167 5. Shrestha NK, Burke PC, Nowacki AS, et al. Necessity of COVID-19 vaccination
- in previously infected individuals. *medRxiv*. 2021; doi:10.1101/2021.06.01.21258176
- 169 6. Doshi P. Covid-19: Do many people have pre-existing immunity? *Bmj*. Sep 17
- 170 2020;370:m3563. doi:10.1136/bmj.m3563
- 171 7. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity
- in cases of COVID-19 and SARS, and uninfected controls. *Nature*. Aug
- 173 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z

- 174 8. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2
- infection in humans: A systematic review. *PloS one*. 2021;16(1):e0245532.
- 176 doi:10.1371/journal.pone.0245532

- 177 9. Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19
- 178 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-
- 2 circulating variants. *medRxiv*. Feb 12 2021;doi:10.1101/2021.02.11.21251585
- 180 10. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-
- 181 CoV-2. Nature. Mar 2021;591(7851):639-644. doi:10.1038/s41586-021-03207-w

Table. Incidence of SARS-CoV-2 infection among employees SARS-CoV-2 naïve, previously infected or vaccinated in a clinical laboratory workforce, 2020-2021

			Follow up time	
SARS-CoV-2 Status	Cohort size	Number of infections	(person-years)	Incidence per 100 PY (95% CI)*
Naive	4313	254	979.7	25.9 (22.8-29.3)
Previously Infected	254	0	74.4	0 (0-5.0)
Fully Vaccinated	739	4	244.5	1.6 (0.04-4.2)

* PY = person-years, 95% Confidence Interval by Poisson Exact test

183